This is a non-promotional website produced and funded by AstraZeneca, intended for UK patients who have been prescribed TEZSPIRE▼ (tezepelumab)
Coming soon: We are currently updating this website with all relevant information for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Please bear with us! You can access Tezspire CRSwNP resources here.
For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma
For UK patients, and their caregivers, aged 18 and over who have been prescribed Tezspire (tezepelumab) for severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
For more information read the patient information leaflet accessible here
For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma
For UK patients, and their caregivers, aged 18 and over who have been prescribed Tezspire (tezepelumab) for severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
For more information read the patient information leaflet accessible here
Tezspire is a medicine that helps people aged 12 and older to manage their severe asthma. It is an add-on maintenance treatment which means that you use it with other asthma medicines to treat severe asthma when the disease isn't under control with these other medicines.
Tezspire works in a different way to your other asthma medicines which is why it may help to: reduce asthma attacks, improve your breathing and ease your asthma symptoms.
You may have heard your doctor call Tezspire 'tezepelumab' as this is the name of the active substance it contains. When triggered, your immune system makes special proteins called 'antibodies' to defend you against harmful substances, like a virus. Tezepelumab is a monoclonal antibody, which means it’s made in a lab, but it works in a similar way to our immune system's natural antibodies.
Tezspire specifically targets a substance called TSLP (thymic stromal lymphopoietin). Find out more about why TSLP is important below.
Tezspire targets a protein released by our immune system, called TSLP which plays a key role in causing inflammation in your airways leading to signs and symptoms of asthma. Tezspire blocks the action of TSLP, to help reduce inflammation and asthma symptoms.
Multiple external triggers, such as pollen, dust mite and cat dander cause the release of TSLP.
TSLP plays a role in causing inflammation in your airways that leads to signs and symptoms of asthma.
By blocking the action of TSLP, Tezspire helps to reduce inflammation and asthma symptoms.
*The exact mechanism by which Tezspire works has not been established.
Your doctor will have prescribed you Tezspire because your severe asthma was not under control even though you were taking other asthma medicines. Tezspire may help to: reduce asthma attacks, improve your breathing, and ease your asthma symptoms.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.ukhttps://yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.
GB-49705 | DOP: February 2024
This site is intended to complement, not replace, the 'Instructions for Use' and 'Patient Information Leaflet' (found in your carton or linked at the top of the page). Refer to these materials for additional important information.
If you have any questions or concerns about your treatment, you should always talk to your healthcare team.
Please see the information in the box above for details on how to report any side effects you may be experiencing.
Welcome to an AstraZeneca UK produced and funded website
Please select the option that applies to you below.
GB-51556 | DOP: March 2024
This is a non-promotional website produced and funded by AstraZeneca, intended for UK patients who have been prescribed TEZSPIRE▼ (tezepelumab)
Coming soon
We are currently updating this website with all relevant information for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Please bear with us! You can access Tezspire CRSwNP resources here.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Side effects can also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
By reporting side effects you can help provide more information on the safety of this medicine.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
